How we Help

How we Help

Our goal is to add commercial value to your compounds by demonstrating human efficacy, investigating human safety and providing better ways to predict human ADME.


Since 2002 Biopta has been rapidly growing its partnerships with companies throughout the world to help them reduce the risks and costs associated with drug development, whilst providing the means to accelerate their compounds through market approval.

We have helped our clients achieve:

 

  • Savings of over $350m in clinical development costs by eliminating compounds that would have failed because of poor human efficacy or human safety issues
  • An average saving of $7 for every $1 invested in predictive human assays

  • Greatly increased commercial value for development compounds, by providing translational evidence of human function to present to investors and licensors.


Our clients, including virtual biotechs, the world's leading pharmaceutical companies or academic institutions, receive the same unrivalled customer experience. Biopta can adapt and respond to changing client demands to deliver quality and useable data in a time and cost effective manner.

 

Live chat by BoldChat